Drug-induced liver injury associated with dacomitinib: A case report
Dacomitinib, the second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been used as a first-line treatment in non-small cell lung cancer (NSCLC) patients harboring EGFR mutation. In this case, we report a patient with drug-induced liver injury (DILI) associated...
| Main Authors: | , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
Frontiers Media S.A.
2022-09-01
|
| 叢編: | Frontiers in Oncology |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fonc.2022.979462/full |